Pancreatic cancer has long resisted most attempts to treat it effectively. It is typically diagnosed late, spreads quickly, and responds poorly to existing therapies. But a new study suggests that it has a hidden vulnerability.
Researchers from The Wistar Institute and ChristianaCare Helen F. Graham Cancer Center & Research Institute have uncovered a previously unrecognized biological dependency that pancreatic tumors appear to rely on for survival. The work, published in the Proceedings of the National Academy of Sciences, reveals that damaged mitochondria inside cancer cells can drive a self-sustaining inflammatory loop — one that the tumor then becomes dependent on.
And when that loop is blocked, the cancer cells die.
The discovery points to a potential new therapeutic target and aligns with the growing consensus that mitochondria are anything but passive in cancer development.
Mitochondria gone wrong
Mitochondria are best known as the cell’s energy generators, producing ATP through oxidative phosphorylation. But their role extends far beyond energy metabolism. Their complex double-membrane structure supports electron transport, redox regulation, calcium homeostasis, and the controlled release of pro-apoptotic factors. These multifaceted functions of mitochondria in normal physiology make them important cellular stress sensors, enabling cells to sense and adapt to changing environmental conditions.
In cancer, these same mitochondrial functions are profoundly reprogrammed. Tumor cells exploit metabolic pathways such as aerobic glycolysis, glutamine metabolism, and lipid synthesis to sustain uncontrolled growth.
For a long time, mitochondria were on the back burner in cancer research because tumors are largely glycolytic. The assumption was that mitochondria weren’t especially important because they don’t drive glycolysis.
—Dario Altieri, The Wistar Institute
“For a long time, mitochondria were on the back burner in cancer research because tumors are largely glycolytic,” Dario Altieri, senior author and President and CEO of The Wistar Institute, told DDN. “The assumption was that mitochondria weren’t especially important because they don’t drive glycolysis. But the field has changed. We now recognize that mitochondria influence far more than metabolism.”
Mitochondria are still essential within tumors, helping cancer cells survive otherwise hostile conditions such as nutrient depletion, hypoxia, and exposure to therapy, and in doing so become central drivers of tumorigenesis. “Many mechanisms of tumor progression, in particular metastasis, depend on mitochondrial metabolism,” said Altieri.
Mitochondrial mass is controlled by two opposing pathways, biogenesis and turnover. These pathways maintain mitochondrial homeostasis and ensure that damaged organelles are removed while functional ones are replenished. This balance is highly dynamic and shaped by metabolic state, tumor heterogeneity, tissue context, microenvironmental stress, and disease stage.
When this balance is disrupted, dysfunctional mitochondria can accumulate and persist within tumor cells, creating conditions in which mitochondrial signals extend beyond metabolism and begin to influence broader cellular behavior.
Damaged mitochondria as signaling hubs
Rather than simply maintaining healthy mitochondria, pancreatic cancer cells were found to accumulate structurally compromised organelles. These damaged mitochondria — also described as “ghost mitochondria” — are not inert. Instead, they function as active signaling hubs within the tumor cell.
A key factor in this transformation is the loss of a key mitochondrial structural protein called Mic60, which helps maintain the integrity of the inner mitochondrial membrane. When Mic60 levels are reduced, the mitochondrial membrane becomes unstable and begins to leak.
This breach allows double-stranded RNA (dsRNA), normally confined within mitochondria, to escape into the cytoplasm. To the cell, this material resembles a viral infection, triggering innate immune sensors designed to detect foreign genetic material.
Mic60 is a critical structural scaffold for mitochondria. It maintains the integrity of the organelle and helps assemble respiratory complexes — so finding that tumors tolerate reduced levels of Mic60, and even exploit the resulting stress, was unexpected.
—Dario Altieri, The Wistar Institute
The researchers identified one pathway, known as TLR3/TRAF6, that activates a strong inflammatory response inside the cancer cell in response to the mitochondrial dsRNA. However, rather than harming the tumor, the inflammation fuels it.
“Mic60 is a critical structural scaffold for mitochondria,” Altieri said. “It maintains the integrity of the organelle and helps assemble respiratory complexes — so finding that tumors tolerate reduced levels of Mic60, and even exploit the resulting stress, was unexpected.”
Inflammation as a survival strategy
Inflammation has long been associated with cancer progression, but it is often viewed as something tumors exploit opportunistically. What makes this discovery different is the degree of dependency.
The researchers found that pancreatic cancer cells become so reliant on this internally generated inflammatory signal that they cannot survive without it. When the pathway was inhibited, cancer cells died. Healthy cells, by contrast, were largely unaffected.
“The effect was selective for pancreatic cancer cells with low Mic60 levels,” Altieri said. “Normal tissues were unaffected, and even tumor cells with higher Mic60 expression were much less sensitive.”
Preclinical models of pancreatic cancer also showed promising results. “In mouse models, we observed sustained inhibition of tumor growth rather than tumor regression,” Altieri said. “In parallel cell-culture experiments, blocking this pathway triggered extensive tumor cell death, suggesting that when this inflammatory dependency is disrupted, cancer cells are unable to compensate and instead undergo necroptotic cell death.”
Reframing mitochondrial dysfunction
This idea resonates with a broader shift in cancer research. Mitochondria are increasingly recognized as central players in tumor–immune interactions, influencing T-cell function, macrophage polarization, natural killer cell activity, and stromal cell behavior within the tumor microenvironment.
If mitochondrial signals can shape immune responses from within cancer cells themselves, they may represent a powerful — and underexplored — class of therapeutic targets.
The researchers are now working to answer two critical questions. First, how exactly does loss of Mic60 destabilize the mitochondrial membrane and allow RNA leakage? Second, can inhibitors of the TLR3/TRAF6 pathway be developed into safe and effective cancer therapies?
Targeting inflammation is inherently complex, given its essential role in normal immune defense. But the apparent selectivity of this pathway provides hope that a therapeutic window may exist.
More broadly, the study underscores how much remains to be learned about cancer development and metastasis.
